Astera Labs: A Top Performance Score With a Sell Signal
Astera Labs (ALAB) carries an 8.4 Performance Score, one of the stronger readings among the Semiconductors names Stoxcraft tracks. Despite that, the stock's own Buy Signal currently reads "Sell." The gap comes down to Risk: ALAB's Risk Score of 9.9 is the highest of any name in this comparison, and it's high enough to override an otherwise strong Performance reading in Stoxcraft's entry-timing model.
The price action explains why. Shares are up 160.01% over six months and 72.51% over the past year, a run that's cooled somewhat lately, down 0.36% today and roughly flat over the past month. Standard deviation of 26.55% and a beta of 3.84 both point to a stock that moves several times harder than the broader market, in both directions. RSI of 48.60 sits in neutral territory right now, but that calm follows a genuinely volatile multi-month stretch. Astera's own investor relations site carries the record Q2 results behind that run.
The Balance Sheet Doesn't Match the Risk Score
Here's the twist: Astera Labs actually carries the strongest Health Score of the three names in this comparison, at 7.3. Total debt of just $35 million against $1.36 billion in equity gives it a current ratio of 10.24, and an Altman Z-Score of 245.93 puts bankruptcy risk essentially off the table. Piotroski Score of 6 out of 9 and a 26.72% net profit margin both point to a fundamentally sound company.
That's what makes the Risk Score of 9.9 worth sitting with. It's not a balance-sheet read, it's a volatility-and-entry read, and a stock trading 160% higher than six months ago with a beta near 4 will score as high-risk almost regardless of how clean the underlying financials are. The Sell signal is Stoxcraft's model saying the timing looks stretched, not that the company itself is in trouble.
How Credo and Aehr Compare
Credo Technology is the group's most complete story. Its Performance Score sits at a perfect 10.0, the maximum Stoxcraft's model assigns, and unlike Astera, that comes paired with an actual Buy signal. Health Score of 7.5, an Altman Z-Score of 117.22, and a 22.89% return on equity back up a 118.88% one-year return and a 1,714.94% three-year return. Risk Score of 9.2 is still high, all three names in this comparison carry real volatility, but it sits just below Astera's. Credo's own investor relations site details the record quarterly revenue behind that run.
Aehr Test Systems is the name to watch most carefully. Its 9.9 Performance Score is nearly as strong as Credo's perfect score, driven by a 591.39% one-year return and 370.55% six-month return on demand for its AI-chip burn-in test systems. But its Health Score of just 1.7 is the weakest of the three by a wide margin. Net income remains negative at -$7.1 million on just $50 million in trailing revenue, and Piotroski Score of 3 out of 9 flags real balance-sheet weakness underneath that price action. Aehr's own Buy Signal reads "Strong Sell," the most cautious reading of the three. Aehr's investor relations site lays out the AI test-system demand driving the rally.
Which Score Holds Up?
All three stocks have delivered real gains this year, and all three sit in the same corner of the semiconductor market: connectivity and testing infrastructure feeding AI data centers. But "top Performance Score" doesn't mean the same thing three times over. Credo pairs its performance with fundamentals and a Buy signal, the closest thing to a clean setup in this group. Astera pairs strong fundamentals with a stretched entry point, a Sell signal that's about timing more than business quality. Aehr pairs its performance with the weakest balance sheet of the three and the market's own most cautious signal, Strong Sell.
None of that means any of the three is a bad business. It means the Performance Score alone, the number that would show up first on a quick scan, tells less than a third of the story here. A Risk Score of 9.9 and a Health Score of 1.7 both matter as much as an 8.4 or a 9.9 on Performance, just in different directions.
The Overall Ratings reflect that spread even though the Performance Scores barely differ. Astera and Credo both land at 3.5 stars, weighed down by their Risk Scores despite strong or near-perfect Performance. Aehr sits half a star lower at 3 stars, the combination of a top-tier Performance Score and the group's weakest Health Score pulling it down even as its one-year return outpaces both peers. A quick scan of price charts alone would rank these three in exactly the reverse order of what their full scorecards actually show.
For a broader view of how ALAB, CRDO, and AEHR compare against the rest of the Semiconductors industry on Health, Performance, and Risk Score, the Stoxcraft Screener lets you filter the full industry by any of the three.
